newsfilter
← Latest News
GlobeNewswire·

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

JSPR
  • Faruqi & Faruqi, LLP is investigating potential securities law violations by Jasper Therapeutics, Inc. (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek lead plaintiff status.
  • Investors who suffered losses exceeding $10,000 between November 30, 2023, and July 3, 2025, are encouraged to contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • The complaint alleges Jasper violated federal securities laws by failing to disclose that third-party manufacturers lacked controls to ensure products met cGMP regulations for clinical trials.
  • Alleged failures to disclose manufacturing issues increased the risk of confounded study results, potentially disrupting regulatory & commercial prospects for the product briquilimab.
  • The lawsuit claims the company overstated its financial & business prospects while failing to disclose the likelihood of disruptive cost-reduction measures.
  • On July 7, 2025, Jasper reported that BEACON Study results were confounded by a defective drug product lot affecting 10 of 13 patients in specific cohorts.
  • The July 7 press release revealed the defective lot was also used in the ETESIAN Study, leading to the study's halt & a pause in asthma development to focus on CSU.
  • Jasper also announced halting development in SCID & implementing cost-cutting measures & potential restructuring after previously claiming a cash runway extending through Q3 2025.
  • Following the July 7 disclosure, Jasper's stock price fell $3.73 per share (55.1%) to close at $3.04.
  • The court-appointed lead plaintiff is the class member with the largest financial interest who directs & oversees litigation on behalf of the putative class.
  • Faruqi & Faruqi invites whistleblowers, former employees, shareholders, & others with information regarding Jasper's conduct to contact the firm.
  • Additional details are available at www.faruqilaw.com/JSPR or by contacting the firm directly.